The BRCA POC Research Assay results will also help identify patients in need of more comprehensive hereditary breast and ovarian cancer screening using affordable NGS panels for BRCA1/2 founder variant-negative patients (approximately ZAR 8000 in the state sector). Here, BRCA1 is linked to ovarian cancer.